Ascentage Pharma Submits Application for Lisaftoclax, a Novel Oral Bcl-2 Inhibitor
Ascentage Pharma (HKG: 6855) has announced that its proprietary oral Bcl-2 selective inhibitor, Lisaftoclax (APG-2575),...
C-Ray Therapeutics Secures Over $100 Million in A+ Round Financing
C-Ray Therapeutics (Chengdu) Co., Ltd., an innovative enterprise in the field of radioactive medicines, has...
Bliss Bio Secures NMPA Approval for BB-1712, Pioneering ADC Therapy
Bliss Bio announced that its Investigational New Drug (IND) application for the innovative antibody-drug conjugate...
Merck KGaA Reports 3.8% Organic Growth in Q3 2024 Financials
Merck KGaA (NYSE: MRK), the German multinational science and technology company, has released its financial...
Impact Therapeutics Secures $34.5 Million in Series D++ Financing for Senaparib Commercialization
China-based biopharmaceutical company Impact Therapeutics has reportedly secured RMB 250 million (USD 34.5 million) in...
GSK’s Blenrep Shows Survival Benefit in Phase III Multiple Myeloma Study
UK-based pharmaceutical company GSK plc (NYSE: GSK) has reported positive results from a Phase III...
Janssen-Cilag’s Nipocalimab Shows Promise in Phase II Study for Sjögren’s Disease
Janssen-Cilag International NV, a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ), has unveiled the...
Sanofi’s Sarclisa Receives CHMP Recommendation for Newly Diagnosed Multiple Myeloma
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that the Committee for Medicinal Products for...
J&J MedTech Secures Exclusive Distribution Deal with Responsive Arthroscopy
Johnson & Johnson (J&J, NYSE: JNJ) MedTech, a leading player in the US medical technology...
Jiangsu Hengrui Receives NMPA Approval for SHR-2173 Clinical Trial in ITP
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...
Eisai and Biogen’s Lecanemab Receives Positive CHMP Opinion for Early Alzheimer’s Treatment
Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced that the...
Merck Secures Exclusive Rights to LaNova’s PD-1/VEGF Bispecific Antibody LM-299
US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced a significant...
China Releases Comprehensive AI Application Guidelines for Healthcare Industry
The National Health Commission, National Administration of Traditional Chinese Medicine, and National Bureau of Disease...
BeiGene Ltd to Become BeOne Medicines Ltd, Emphasizing Global Oncology Commitment
China-based biotechnology company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced a proposed...
Beijing Biostar Partners with Baheal for Utidelone Market Promotion in China
Beijing Biostar Technologies Ltd (HKG: 2563), a synthetic biology-driven anti-tumor drug specialist that made its...
NMPA Issues Interim Provisions for Overseas MAHs’ Designated Domestic Responsible Persons
The National Medical Products Administration (NMPA) has released the “Interim Provisions on the Management of...
Sino Biopharmaceutical’s TQB3002 Receives FDA Clearance for Phase I Study
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based pharmaceutical company, has announced that it has...
PegBio Files for IPO on Hong Kong Stock Exchange
PegBio Co., Ltd., a specialist in endocrine metabolism based in Suzhou, has taken a significant...
Mabwell Bioscience Receives NMPA Approval for 9MW2821 Clinical Trials
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...
WuXi Biologics Expands Sterile Filling Capabilities in Germany with New Line
China’s Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced plans...